Market closedNon-fractional

Theravance Biopharma/TBPH

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Theravance Biopharma

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Ticker

TBPH

Sector

Healthcare

Trading on

NASDAQ

Industry

Pharmaceuticals

Headquarters

South San Francisco, United States

Employees

99

TBPH Metrics

BasicAdvanced
$414M
Market cap
-
P/E ratio
-$0.87
EPS
0.36
Beta
-
Dividend rate
$414M
0.36
5.738
5.292
21.399
21.399
-16.95%
-5.65%
-15.56%
7.145
2
2
-23.833
26.65%
-106.98%
-2.45%
-41.44%

What the Analysts think about TBPH

Analyst Ratings

Majority rating from 5 analysts.
Buy

TBPH Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-80.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$15M
-17.14%
Net income
-$12M
36.47%
Profit margin
-80.00%
64.71%

TBPH Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.51%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.28
-$0.17
-$0.17
-$0.24
-
Expected
-$0.21
-$0.21
-$0.15
-$0.25
-$0.21
Surprise
33.33%
-18.92%
14.35%
-5.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Theravance Biopharma stock?

Theravance Biopharma (TBPH) has a market cap of $414M as of July 06, 2024.

What is the P/E ratio for Theravance Biopharma stock?

The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of July 06, 2024.

Does Theravance Biopharma stock pay dividends?

No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Theravance Biopharma dividend payment date?

Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.

What is the beta indicator for Theravance Biopharma?

Theravance Biopharma (TBPH) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Theravance Biopharma stock

Buy or sell Theravance Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing